One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
AIDS Vaccine Research: An overview
This series of infographics highlights the current state of the field. Each research area is expanded with key details about the current focus and advancements in the science along with critical issues that advocates should be tracking.
HIV Vaccines by the Numbers: Trials, discoveries, money and more
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphics represents key facts about the AIDS vaccine field.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
Viral Load Testing Delivers Systemic Benefits from the Individual to the Institution
This graphic from AVAC Report 2013 highlights the benefits of routine viral load testing for both individuals and institutions. Expanding access to viral load testing is a key step toward achieving virologic suppression.
The Global HIV Treatment U=U Gap: Existing people on ART versus people eligible under past and current WHO guidelines
This year WHO released eagerly anticipated comprehensive antiretroviral Treatment U=U (ART) guidelines addressing how to optimize ART for both Treatment U=U and prevention. The guidance recommends raising the CD4 threshold for Treatment U=U initiation to 500 CD4 cells or below — with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As this graphic from AVAC Report 2013 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it.
2013 WHO ARV guidelines can decrease new infections and deaths
WHO 2013 guidelines recommend initiating ART in HIV positive people with CD4 cell counts of 500 or below. This graphic from AVAC Report 2013 illustrates how implementing these guidelines will reduce infections and save lives.
From Research to Rollout: Evaluations that move a product to the “real world”
The Tipping Point: Understanding a crucial milestone in the AIDS response
A Three-Part Agenda for Ending AIDS 2014
The Px Wire centerspread from January-March Volume 7, No. 1 lays out the “research-to-rollout” continuum of steps between initial evaluations of a novel concept for HIV prevention and the ultimate introduction of new tool offered in an effective public health program.